1. Clinical and biological implications of Hippo pathway dysregulation in sarcomas
- Author
-
Kyriazoglou Anastasios, Zakopoulou Roubini, Zagouri Flora, Bamias Aristotelis, and Dimopoulos Meletios Athanasios
- Subjects
sarcomas ,hippo pathway ,yap ,taz ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Sarcomas are mesenchymal malignant tumors with poor prognosis and limited treatment options. Hippo pathway is a recently discovered pathway normally involved in organ development and wound healing. Hippo signaling is often altered in solid tumors. The molecular elements of Hippo signaling include MST1/2 and LATS1/2 kinases which phosphorylate and regulate the activity of YAP and TAZ co-transcriptional activators. Hippo pathway cross-talks with several molecular pathways with known oncogenic function. In sarcomas Hippo signaling plays a pivotal role in tumorigenesis, evolution and resistance in chemotherapy regimens. Targeting Hippo pathway could potentially improve prognosis and outcome of sarcoma patients.
- Published
- 2019
- Full Text
- View/download PDF